Cerebrolysin and P21 both come up in conversations about brain health and neuroprotection, but they are very different compounds with very different levels of evidence and availability.
Quick answer: Cerebrolysin is an injectable peptide preparation derived from pig brain tissue, used in some countries for stroke, dementia, and traumatic brain injury, and it has more human clinical history, though it is not FDA-approved in the United States. P21 (P021) is an investigational research peptide derived from a CNTF fragment, studied mainly in preclinical models for neurogenesis and tau-related effects, with limited human data. Cerebrolysin has the larger clinical track record; P21 remains experimental. Neither is an approved drug in the US, and both should only be considered with medical guidance.
Cerebrolysin vs P21 comparison
| Feature | Cerebrolysin | P21 (P021) |
|---|---|---|
| Source | Pig brain-derived peptides | CNTF fragment-derived peptide |
| Form | Injectable | Research peptide |
| Evidence | More human clinical use abroad | Mostly preclinical |
| US FDA status | Not approved | Not approved, investigational |
| Studied for | Stroke, dementia, TBI | Neurogenesis, tau effects |
| Maturity | Established abroad | Experimental |
Is Cerebrolysin FDA-approved in the United States?
No. Cerebrolysin is not FDA-approved in the United States. It is used in a number of other countries for conditions such as stroke recovery, dementia, and traumatic brain injury, where it has accumulated clinical use and study. In the US, it does not have approval, which affects its legal availability and oversight. Anyone considering it should understand that US regulatory review has not cleared it, and quality and sourcing outside approved channels can be uncertain.
What is P21 and what does the research show?
P21, also written P021, is a research peptide derived from a fragment of ciliary neurotrophic factor (CNTF). It has been studied mainly in preclinical models, where researchers examined effects on neurogenesis (the formation of new neurons) and on tau, a protein involved in some neurodegenerative diseases. The work is largely at the animal or laboratory stage, and strong human clinical data are limited. So P21 is best described as experimental, with interesting preclinical signals but not the human evidence base needed to draw firm conclusions.
From the FormBlends catalog
P21 (P021)
Neurotrophic peptide that promotes neurogenesis in the adult brain · From $54/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
Learn about P21 (P021) →Does P21 promote hair growth?
Claims that P21 promotes hair growth are not established by reliable evidence. P21 research has centered on neurological effects, not hair. Hair-growth assertions appear to come from online sources rather than published clinical data. Treat such claims with skepticism, since they are not supported by the research that actually exists on this peptide.
Cerebrolysin vs Pinealon and other comparisons
People sometimes compare Cerebrolysin with shorter peptides like Pinealon, which is marketed in the nootropic space. These comparisons mix compounds with very different evidence levels. Cerebrolysin has a substantial clinical literature abroad, while many short nootropic peptides have far less rigorous human data. When comparing any of these, weigh the strength and source of the evidence, regulatory status, and how the compound is administered, rather than marketing claims.
Nasal versus intramuscular and effectiveness
Route of administration differs across these compounds; Cerebrolysin is typically given by injection, while some research peptides are explored via other routes. Effectiveness comparisons between P21 and Cerebrolysin are not well supported, because P21's human data are limited. Without head-to-head human trials, claims that one is clearly more effective are speculative. The honest summary is that Cerebrolysin has more clinical history, and P21 is still experimental.
What this means for you
Both compounds sit outside FDA approval in the US, and one (P21) is largely preclinical. If brain health is your concern, evidence-based steps (sleep, exercise, cardiovascular health, managing blood pressure and blood sugar) have far stronger support. Discuss any interest in these peptides with a clinician. FormBlends focuses on medically supervised weight management; metabolic health also supports brain health. See our provider comparison tool if weight is part of your goals.
Frequently asked questions
Is Cerebrolysin FDA-approved in the US?
No. It is used in some other countries but is not approved in the United States.
What is P21?
A research peptide derived from a CNTF fragment, studied mostly in preclinical models.
Which has more evidence?
Cerebrolysin has more human clinical history; P21 is largely preclinical.
Does P21 grow hair?
That claim is not supported by reliable evidence.
Are either of these approved drugs?
Neither is FDA-approved in the US; P21 is investigational.
Is one more effective than the other?
There is no solid head-to-head human evidence, so such claims are speculative.
Should I use them?
Only with a clinician's guidance, given the limited US approval and evidence.
Sources
- StatPearls and peer-reviewed overviews of Cerebrolysin: https://www.ncbi.nlm.nih.gov/books/
- PubMed listings for P021/CNTF peptide research: https://pubmed.ncbi.nlm.nih.gov/
Related guides
- Cerebrolysin Peptide Brain Health Neuroprotection
- Cerebrolysin For Brain Fog: Complete Guide
- Best Peptide for Brain Health and Cognition
- Nootropic Peptides Ranked: Semax, Selank, Dihexa, P21
- Neurogenesis Research and GLP-1
- Reduce Hip Fat Glp-1 Targeted
Ready when you are
P21 (P021)
Neurotrophic peptide that promotes neurogenesis in the adult brain · From $54/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
Learn about P21 (P021) →